Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
Longeveron (NASDAQ: LGVN) announced the U.S. Patent and Trademark Office granted U.S. Patent No. 12,465,620 for a method of treating aging-related frailty with inflammaging using human mesenchymal stem cells. The patent provides U.S. rights through 2038, with potential for patent-term or regulatory exclusivity extensions.
The company’s lead MSC therapy, laromestrocel, has delivered positive initial results across two clinical trials and prior Phase 1 and 2 studies were designed to show improvements in the six-minute walk test and physical functioning in aging-related frailty patients. Aging-related frailty is described as a multisystem syndrome linked to inflammaging.
Longeveron (NASDAQ: LGVN) ha annunciato che l'U.S. Patent and Trademark Office ha concesso la U.S. Patent No. 12,465,620 per un metodo di trattamento dell'aging-related frailty con inflammaging attraverso cellule staminali mesenchimali umane. Il brevetto garantisce diritti negli Stati Uniti fino al 2038, con possibilità di estensioni della durata del brevetto o di esclusività regolatoria.
La terapia MSC leader dell'azienda, laromestrocel, ha mostrato risultati positivi iniziali in due studi clinici e studi di Fase 1 e 2 precedenti erano progettati per dimostrare miglioramenti nel test di camminata di sei minuti e nel funzionamento fisico in pazienti affetti da fragilità legata all'invecchiamento. La fragilità legata all'invecchiamento è descritta come una sindrome multisistemica legata all'inflammaging.
Longeveron (NASDAQ: LGVN) anunció que la Oficina de Patentes y Marcas de Estados Unidos concedió la Patente de los EE. UU. No. 12,465,620 para un método de tratar la fragilidad relacionada con el envejecimiento mediante inflammaging utilizando células madre mesenquimales humanas. La patente otorga derechos en EE. UU. hasta el 2038, con posibilidad de extensiones de la duración de la patente o de exclusividad regulatoria.
La terapia MSC principal de la empresa, laromestrocel, ha dado resultados iniciales positivos en dos ensayos clínicos, y estudios de Fase 1 y 2 anteriores estaban diseñados para mostrar mejoras en la prueba de caminata de seis minutos y en el funcionamiento físico en pacientes con fragilidad relacionada con el envejecimiento. La fragilidad relacionada con el envejecimiento se describe como un síndrome multisistémico vinculado a inflammaging.
Longeveron (NASDAQ: LGVN)은 미국 특허상표청이 노화 관련 허약(inflammaging)을 인간의 중간엽 줄기세포를 사용하여 치료하는 방법에 대해 미국 특허번호 12,465,620을 부여했다고 발표했습니다. 특허는 미국 내 권리를 2038년까지 제공하며 특허 기간 연장이나 규제 독점권의 가능성이 있습니다.
회사의 선두 MSC 치료제인 laromestrocel은 두 건의 임상시험에서 긍정적인 초기 결과를 보여주었고, 이전의 1상 및 2상 연구는 노화 관련 허약 환자에서 6분 보행 검사 및 신체 기능의 개선을 입증하도록 설계되었습니다. 노화 관련 허약은 inflammaging과 관련된 다계통 증후군으로 설명됩니다.
Longeveron (NASDAQ : LGVN) a annoncé que le Bureau américain des brevets et des marques a accordé le brevet n° 12,465,620 pour une méthode de traitement de la fragilité liée à l'âge par inflammaging utilisant des cellules souches mésenchymateuses humaines. Le brevet offre des droits aux États-Unis jusqu'en 2038, avec possibilité d'extensions de la durée du brevet ou d'exclusivité réglementaire.
La thérapie MSC phare de l'entreprise, laromestrocel, a donné des résultats initiaux positifs dans deux essais cliniques et les études de phase 1 et 2 précédentes étaient conçues pour démontrer des améliorations dans le test de marche de six minutes et le fonctionnement physique chez les patients atteints de fragilité liée à l'âge. La fragilité liée à l'âge est décrite comme un syndrome multisystémique lié à l'inflammage.
Longeveron (NASDAQ: LGVN) gab bekannt, dass das United States Patent and Trademark Office das US-Patent Nr. 12,465,620 für eine Methode zur Behandlung von altersbedingter Gebrechlichkeit mit inflammaging unter Verwendung menschlicher mesenchymalischer Stammzellen erteilt hat. Das Patent gewährt Rechte in den USA bis zum 2038, mit der Möglichkeit von Verlängerungen der Patentlaufzeit oder regulatorischer Exklusivität.
Die führende MSC-Therapie des Unternehmens, laromestrocel, hat in zwei klinischen Studien positive anfängliche Ergebnisse geliefert, und frühere Phase-1- und Phase-2-Studien waren darauf ausgelegt, Verbesserungen im Six-Minute-Walk-Test und der körperlichen Funktionsfähigkeit bei Patienten mit altersbedingter Gebrechlichkeit zu zeigen. Altersbedingte Gebrechlichkeit wird als multisystemisches Syndrom beschrieben, das mit inflammaging verbunden ist.
Longeveron (NASDAQ: LGVN) أعلنت أن مكتب البراءات والعلامات التجارية الأمريكي منح البراءة الأمريكية رقم 12,465,620 لطريقة علاج الضعف المرتبط بالشيخوخة باستخدام inflammaging باستخدام الخلايا الجذعية شديدة التمايز البشرية. تمنح البراءة حقوقاً في الولايات المتحدة حتى 2038، مع إمكانية تمديد فترة البراءة أو حصرية تنظيمية.
علاج MSC الرائد للشركة، laromestrocel، قدم نتائج إيجابية أولية عبر تجربتين سريريتين وكانت الدراسات السابقة من المرحلة 1 و2 مصممة لإظهار تحسنات في اختبار المشي لمدة ست دقائق والوظيفة البدنية لدى مرضى الضعف المرتبط بالشيخوخة. يتم وصف الضعف المرتبط بالشيخوخة كمتلازمة متعددة الأجهزة مرتبطة بـ inflammaging.
- U.S. Patent No. 12,465,620 granted for MSC frailty treatment
- Patent provides U.S. rights through 2038
- Laromestrocel reported positive initial results across two clinical trials
- Laromestrocel remains a clinical-stage therapy with no approval cited
- Patent term is finite through 2038 (extensions possible only)
Insights
USPTO grant for laromestrocel method through
The patent grants targeted U.S. rights for administering allogeneic mesenchymal stem cells to patients with aging‑related frailty linked to inflammaging, covering a defined therapeutic method. This creates a clearer intellectual property barrier around the company’s proprietary MSC approach and supports differentiation of Longeveron’s laromestrocel in the aging‑frailty space.
Key dependencies include the patent scope, claim breadth, and enforceability against similar MSC regimens; these will determine commercial and partnership value. Regulatory exclusivity and any patent term extensions could extend protection beyond
Concrete items to watch: the specific claim language and granted claim scope, any follow‑on U.S. filings or oppositions, and clinical readouts that align with the patented method (notably endpoints like the six‑minute walk test). Expect these items to influence licensing or collaboration discussions within the next 12–36 months.
- The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging
- No approved treatments for aging-related frailty, a syndrome affecting older individuals that impairs human Healthspan, and is characterized by weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss
- Laromestrocel, a mesenchymal stem cell therapy, has delivered positive initial results across two clinical trials in aging-related frailty
MIAMI, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering administration of the Company’s proprietary Mesenchymal Stem Cells (MSCs) for the treatment of patients with symptoms of aging-related frailty.
U.S. Patent No. 12,465,620, entitled “Method of Treating Aging Frailty in Subjects with Inflammaging Using Human Mesenchymal Stem Cells,” provides Longeveron with patent rights in the United States through 2038. Further patent term extension may occur along with regulatory exclusivity extensions.
Aging-related frailty is a syndrome of multisystem physiological dysregulation occurring in older individuals which diminishes human healthspan. The symptoms of aging-related frailty include weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss. Many studies show a direct correlation between aging-related frailty and inflammation. Inflammaging has received considerable attention because it proposes a link between immune changes and a number of diseases and conditions (such as aging-related frailty) common in old age.
Longeveron has previously conducted Phase 1 and 2 studies in aging-related frailty designed to show improvements in the six-minute walk test and physical functioning for its lead MSC drug, laromestrocel.
About laromestrocel (Lomecel-B®)
Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young healthy adult donors. These specialized cells, known as mesenchymal signaling cells (MSCs), are essential to our endogenous biological repair mechanism. MSCs have been shown to perform a number of complex functions in the body, including the formation of new tissue. They also have been shown to respond to sites of injury or disease and secrete bioactive factors that are immunomodulatory and regenerative. We believe that laromestrocel MSCs may have multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
What did Longeveron announce on November 12, 2025 about LGVN?
How long does the new LGVN U.S. patent last?
What evidence supports Longeveron’s laromestrocel for frailty (LGVN)?
Does the LGVN patent mean laromestrocel is FDA-approved?
What does the LGVN patent cover specifically?
Will the LGVN patent stop competitors immediately from using MSCs for frailty in the U.S.?
